These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 22471520)
1. Protein expression changes in ovarian cancer during the transition from benign to malignant. Waldemarson S; Krogh M; Alaiya A; Kirik U; Schedvins K; Auer G; Hansson KM; Ossola R; Aebersold R; Lee H; Malmström J; James P J Proteome Res; 2012 May; 11(5):2876-89. PubMed ID: 22471520 [TBL] [Abstract][Full Text] [Related]
2. Comparative proteomics of ovarian epithelial tumors. An HJ; Kim DS; Park YK; Kim SK; Choi YP; Kang S; Ding B; Cho NH J Proteome Res; 2006 May; 5(5):1082-90. PubMed ID: 16674097 [TBL] [Abstract][Full Text] [Related]
3. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue. Haslene-Hox H; Oveland E; Woie K; Salvesen HB; Wiig H; Tenstad O Biochim Biophys Acta; 2013 Nov; 1834(11):2347-59. PubMed ID: 23707566 [TBL] [Abstract][Full Text] [Related]
4. Discovery of serum biomarkers implicated in the onset and progression of serous ovarian cancer in a rat model using iTRAQ technique. Huang Y; Zhang X; Jiang W; Wang Y; Jin H; Liu X; Xu C Eur J Obstet Gynecol Reprod Biol; 2012 Nov; 165(1):96-103. PubMed ID: 22818854 [TBL] [Abstract][Full Text] [Related]
5. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics. Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041 [TBL] [Abstract][Full Text] [Related]
6. Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging. Sinclair J; Metodieva G; Dafou D; Gayther SA; Timms JF J Proteomics; 2011 Apr; 74(4):451-65. PubMed ID: 21237297 [TBL] [Abstract][Full Text] [Related]
7. In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome. Sinha A; Ignatchenko V; Ignatchenko A; Mejia-Guerrero S; Kislinger T Biochem Biophys Res Commun; 2014 Mar; 445(4):694-701. PubMed ID: 24434149 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: a strategy for identification of candidate cancer biomarkers. Wang H; Kachman MT; Schwartz DR; Cho KR; Lubman DM Proteomics; 2004 Aug; 4(8):2476-95. PubMed ID: 15274142 [TBL] [Abstract][Full Text] [Related]
9. Early inflammatory response in epithelial ovarian tumor cyst fluids. Kristjánsdóttir B; Partheen K; Fung ET; Yip C; Levan K; Sundfeldt K Cancer Med; 2014 Oct; 3(5):1302-12. PubMed ID: 24947406 [TBL] [Abstract][Full Text] [Related]
10. Variation in cell signaling protein expression may introduce sampling bias in primary epithelial ovarian cancer. Mittermeyer G; Malinowsky K; Beese C; Höfler H; Schmalfeldt B; Becker KF; Avril S PLoS One; 2013; 8(10):e77825. PubMed ID: 24204986 [TBL] [Abstract][Full Text] [Related]
11. Proteome profiling of human epithelial ovarian cancer cell line TOV-112D. Gagné JP; Gagné P; Hunter JM; Bonicalzi ME; Lemay JF; Kelly I; Le Page C; Provencher D; Mes-Masson AM; Droit A; Bourgais D; Poirier GG Mol Cell Biochem; 2005 Jul; 275(1-2):25-55. PubMed ID: 16335783 [TBL] [Abstract][Full Text] [Related]
12. High GOLPH3 expression is associated with a more aggressive behavior of epithelial ovarian carcinoma. Ma Y; Ren Y; Zhang X; Lin L; Liu Y; Rong F; Wen W; Li F Virchows Arch; 2014 Apr; 464(4):443-52. PubMed ID: 24458516 [TBL] [Abstract][Full Text] [Related]
13. Human epithelial-type ovarian tumour marker beta-2-microglobulin is regulated by the TGF-β signaling pathway. Sun W; Gui L; Zuo X; Zhang L; Zhou D; Duan X; Ren W; Xu G J Transl Med; 2016 Mar; 14():75. PubMed ID: 26983758 [TBL] [Abstract][Full Text] [Related]
14. Depletion of Dicer promotes epithelial ovarian cancer progression by elevating PDIA3 expression. Zhu Y; Cai L; Guo J; Chen N; Yi X; Zhao Y; Cai J; Wang Z Tumour Biol; 2016 Oct; 37(10):14009-14023. PubMed ID: 27492604 [TBL] [Abstract][Full Text] [Related]
15. Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics. Qu H; Chen Y; Cao G; Liu C; Xu J; Deng H; Zhang Z Oncotarget; 2016 Dec; 7(50):83187-83199. PubMed ID: 27825122 [TBL] [Abstract][Full Text] [Related]
16. Molecular diagnosis in type I epithelial ovarian cancer. Sadłecki P; Walentowicz-Sadłecka M; Grabiec M Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228 [TBL] [Abstract][Full Text] [Related]
17. Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies. Timms JF; Arslan-Low E; Kabir M; Worthington J; Camuzeaux S; Sinclair J; Szaub J; Afrough B; Podust VN; Fourkala EO; Cubizolles M; Kronenberg F; Fung ET; Gentry-Maharaj A; Menon U; Jacobs I Proteomics Clin Appl; 2014 Dec; 8(11-12):982-93. PubMed ID: 25290619 [TBL] [Abstract][Full Text] [Related]
18. Quantitative proteome analysis of ovarian cancer tissues using a iTRAQ approach. Wang LN; Tong SW; Hu HD; Ye F; Li SL; Ren H; Zhang DZ; Xiang R; Yang YX J Cell Biochem; 2012 Dec; 113(12):3762-72. PubMed ID: 22807371 [TBL] [Abstract][Full Text] [Related]
19. Defective expression of Protein 4.1N is correlated to tumor progression, aggressive behaviors and chemotherapy resistance in epithelial ovarian cancer. Xi C; Ren C; Hu A; Lin J; Yao Q; Wang Y; Gao Z; An X; Liu C Gynecol Oncol; 2013 Dec; 131(3):764-71. PubMed ID: 23994105 [TBL] [Abstract][Full Text] [Related]
20. Fibrillar type I collagen matrices enhance metastasis/invasion of ovarian epithelial cancer via β1 integrin and PTEN signals. Shen Y; Shen R; Ge L; Zhu Q; Li F Int J Gynecol Cancer; 2012 Oct; 22(8):1316-24. PubMed ID: 23013730 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]